Emergence Therapeutics AG

https://www.emergencetx.com

Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers. Its lead program uses innovative linker technology and payload technology to target Nectin-4 – an important and validated target for a broad range of cancers. Furthermore, Emergence is actively exploring opportunities to develop further best- or first-in-class ADCs driven by therapeutic need. Emergence has entered into a licensing and collaboration agreement with SATT Sud-Est (the regional tech transfer office for Aix-Marseille Université, CNRS and Inserm) through which the Company has been granted exclusive rights to a set of anti-Nectin-4 antibodies developed by Dr. Marc Lopez at the Cancer Research Center of Marseille, France. SATT Sud-Est is also providing financial support to the Emergence program. Emergence has also entered into a licensing and collaboration agreement with Heidelberg Pharma Research GmbH, a subsidiary of Heidelberg Pharma AG (FWB: HPHA). Through this agreement Emergence has access to Heidelberg Pharma’s amanitin-based payloads and corresponding linkers (proprietary ATAC Technology). Heidelberg Pharma Research is also a founding investor in Emergence. Nectin-4 has been clinically validated as an ADC target by enfortumab vedotin, recently approved for the treatment of urothelial cancers by the US Food and Drug Administration. Nectin-4 is highly expressed by many different cancers and has a limited expression in healthy tissues, especially compared to many other ADC targets. Emergence is developing a new Nectin-4 ADC with the potential to be a best-in-class ADC. Emergence is led by a strong management team and is supported by a network of world-leading scientists who have contributed significantly to the field of immuno-oncology. The Company is backed by a strong syndicate of European investors including Bpifrance, Gründerfonds Ruhr, Heidelberg Pharma Research GmbH, High-Tech Gründerfonds, idinvest Partners, Kurma Partners and NRW.Bank. Emergence is based in Duisburg, Germany with a subsidiary in Marseille, France. *

	Start	2019-11-26 established
	Group	Eli Lilly (Group)
	Industry	BIOTECH
	Industry 2	antibody-drug conjugate (ADC)
	Person	Elands, Jacobus P. M. (Jack) (Emergence Therapeutics 202006 CEO + Blink Biomedical 201510– CEO before Amakem CEO)
	Person 2	Dehning, Carsten (Emergence Therapeutics 202006 CFO before Albireo 201204 CFO before DeveloGen CFO)

	Region	Duisburg
	Country	Germany
	Street	210 Schifferstr.
	City	47059 Duisburg
		Address record changed: 2022-09-17

Basic data	Employees	n. a.

		* Document for »About Section«: High-Tech Gründerfonds Management GmbH. (11/25/20). "Press Release: Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing".

		Record changed: 2023-12-30